CJC-1295 (No DAC) vs Ipamorelin: Research Comparison Guide (2026)

Two of the most studied growth hormone secretagogues in peptide research, CJC-1295 (No DAC) and Ipamorelin take completely different routes to the same destination. Understanding how they differ, and why researchers often study them together, comes down to receptor biology.

Quick Summary

Not sure which compound fits your research goals? Take our 60-second quiz to get a personalized recommendation.

What Is CJC-1295 (No DAC)?

CJC-1295 (No DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of the first 29 amino acids of native GHRH. The “No DAC” label distinguishes it from a variant that includes a Drug Affinity Complex for extended albumin binding.

The mechanism is direct: CJC-1295 binds to GHRH receptors on pituitary somatotroph cells and stimulates pulsatile growth hormone release. The “No DAC” variant maintains a half-life closer to endogenous GHRH, which means GH release follows a more physiological pulsatile pattern rather than the prolonged blunted secretion seen with DAC variants.

Published research from 2006 (PMID: 16352683) demonstrated that CJC-1295 produced sustained stimulation of GH and IGF-1 in healthy adults with an acceptable safety profile. A companion study (PMID: 17018654) confirmed that pulsatile secretion patterns persisted even during continuous stimulation, which is a key characteristic that distinguishes it from synthetic alternatives.

Research areas include:

• Growth hormone secretion patterns
• IGF-1 stimulation and downstream effects
• Pituitary function
• Body composition in animal models

What Is Ipamorelin?

Ipamorelin is a pentapeptide and the first compound classified as a selective growth hormone secretagogue. It was developed by Novo Nordisk and identified through research into compounds lacking the central dipeptide of GHRP-1.

The mechanism runs through an entirely different receptor system. Ipamorelin binds to ghrelin receptors (also called GHS receptors, for growth hormone secretagogue receptors) on pituitary cells. This is a separate pathway from GHRH signaling. The result is GH release, but without the off-target receptor activity that complicates other secretagogues.

That selectivity is the headline finding in the landmark 1998 paper in the European Journal of Endocrinology (PubMed: 9849822): Ipamorelin stimulates GH release without affecting ACTH, cortisol, prolactin, or FSH/LH levels. Most other GHRP compounds at the time elevated cortisol alongside GH, making Ipamorelin’s clean selectivity profile notable.

A 2020 comprehensive review in JCSM Rapid Communications further detailed the ghrelin receptor pathway and Ipamorelin’s place in the secretagogue development history, positioning it as a reference compound for selectivity research.

Research areas include:

• Selective GH secretion via ghrelin receptor
• Ghrelin receptor pharmacology
• Body composition studies
• Bone density research
• Gastrointestinal motility (ghrelin receptors are present in the gut)

The Key Difference: Two Pathways to GH Release

This is where the science gets interesting. CJC-1295 and Ipamorelin do not compete, they complement.

CJC-1295 stimulates the GHRH receptor. Ipamorelin stimulates the ghrelin/GHS receptor. These are two independent signaling pathways that converge on the same outcome: GH secretion from the anterior pituitary.

The analogy researchers often use is that the pituitary has two separate “on switches” for GH release. CJC-1295 hits one switch. Ipamorelin hits the other. Together, they can stimulate more GH release than either would achieve alone through complementary mechanisms, which is why combination protocols appear in research literature studying GH optimization strategies.

The selectivity difference matters for research design. If a study wants to examine isolated GH elevation without cortisol changes, Ipamorelin is the cleaner tool. If a study wants to examine GHRH pathway signaling specifically, CJC-1295 (No DAC) provides that specificity while maintaining physiological pulsatile patterns.

Research Context Comparison

CJC-1295 research strengths:

• Strong pharmacokinetic data from the 2006 human studies
• Well-characterized effect on both GH and IGF-1
• Valuable for studying downstream anabolic signaling via IGF-1 elevation
• Pulsatile release pattern makes it a good model for physiological GH dynamics

Ipamorelin research strengths:

• Benchmark compound for selectivity studies (no cortisol/ACTH effect)
• Useful for ghrelin receptor pharmacology research
• Clean safety profile makes it well-suited for longer-duration animal studies
• GI motility research, where ghrelin receptors play a known role

Where they overlap:

• Both useful for body composition studies in preclinical models
• Both relevant to bone density research
• Both studied in the context of age-related GH decline

Summary: Which to Study and When

If your research question involves GHRH receptor signaling, pulsatile GH secretion patterns, or downstream IGF-1 effects, CJC-1295 (No DAC) is the more targeted tool.

If your research question involves ghrelin receptor pharmacology, GH selectivity (specifically the absence of cortisol and ACTH elevation), or you need a secretagogue with a clean off-target profile, Ipamorelin is the better fit.

For research examining combined GH stimulation through complementary pathways, these compounds are frequently studied together precisely because their mechanisms do not overlap.

The “which is better” framing misses the point. They answer different research questions. Understanding the receptor biology makes the choice obvious for any given study design.

If this research interests you, Concordia Research Chems carries pharmaceutical-grade CJC-1295 (No DAC) and Ipamorelin with third-party testing. Browse the full catalog or take the quiz to find your starting point.

Related guides: CJC-1295 Complete Research Guide | Ipamorelin Complete Research Guide | Growth Hormone Secretagogues Overview